The Column Group launches a novel ‘venture-biotech’ model, creating an integrated ecosystem to exclusively fund, discover, and develop single-asset biologic therapies.
We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG
The Column Group announces the hiring of Dr. Hui Tian. Previously, Dr. Tian was a founding member of NGM Biopharmaceuticals and most recently served as
The Column Group announces the promotion of Dr. Sarah Hymowitz from Venture Partner to Partner. Dr. Hymowitz has been with TCG since 2021.
The Column Group announces the hiring of Mr. Jeff Goater. Previously, Mr. Goater served as Chief Executive Officer of Surface Oncology. Prior to Surface, he
The Column Group announces the hiring of Dr. Sarah Gillmor Hymowitz. Previously, Dr. Hymowitz spent 22 years at Genentech rising to Vice President of Protein
Widely considered to be the father of the biotechnology industry, Robert Swanson changed the world when he founded Genentech with Herbert Boyer in 1976. TCG’s
February 5, 2019